Anticancer perspectives of monocarbonyl analogs of curcumin: A decade (2014–2024) review

Abstract Monocarbonyl analogs of curcumin (MACs) represent structurally modified versions of curcumin. The existing literature indicates that MACs exhibit enhanced anticancer properties compared with curcumin. Numerous research articles in recent years have emphasized the significance of MACs as effective anticancer agents. This review focuses on the latest advances in the anticancer potential of MACs, from 2014 to 2024, including discussions on their mechanism of action, structure–activity relationship (SAR), and in silico molecular docking studies.